文献速递间质性肺疾病

Tralokinumab治疗特发性肺纤维化的2期随机对照研究

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

本研究为2期随机对照试验,评估抗IL-13单克隆抗体tralokinumab(400 mg或800 mg静脉给药,每4周一次,共68周)治疗轻中度特发性肺纤维化(IPF)的疗效与安全性。因中期分析显示缺乏疗效,研究提前终止;两个剂量组均未达到主要终点(第52周FVC占预计值百分比自基线的变化),安全性可接受。

要点

  • tralokinumab 400 mg与800 mg均未达到第52周FVC占预计值百分比变化的主要终点。
  • 因中期分析缺乏疗效,研究提前终止。
  • 安全性可接受,最常见不良事件为咳嗽、IPF进展与加重、上呼吸道感染。

核心结论

  • tralokinumab安全性及耐受性可接受,但未达到关键疗效终点。

研究设计与样本

  • 2期随机对照研究,受试者为轻中度特发性肺纤维化(IPF)患者。
  • 受试者接受tralokinumab 400 mg、800 mg或安慰剂静脉给药,每4周一次,共68周。
  • 主要终点为意向治疗人群第52周FVC占预计值百分比自基线的变化。

主要发现

  • tralokinumab 400 mg组第52周FVC占预计值百分比自基线的最小二乘均值差(95%CI)为-1.77(-4.13至0.59)(P=0.140)。
  • tralokinumab 800 mg组第52周FVC占预计值百分比自基线的最小二乘均值差(95%CI)为-1.41(-3.73至0.91)(P=0.234)。
  • 在按基线血清骨膜蛋白浓度高于/低于中位数划分的亚组中,两个治疗组的主要终点也均未达到。
  • 第52周FVC占预计值百分比下降大于或等于10%的受试者比例,tralokinumab治疗组在数值上高于安慰剂组。

关键数值与推荐

  • tralokinumab 400 mg、800 mg与安慰剂组最常见的治疗中出现的不良事件分别为咳嗽(17.5%、30.5%、22.8%)、IPF进展与加重(21.1%、16.9%、22.8%)、上呼吸道感染(17.5%、20.3%、12.3%)。
  • 临床试验注册号:NCT01629667。

临床怎么用

  • 对于轻中度IPF患者,不推荐使用tralokinumab以期改善FVC,因2期研究未显示疗效且研究提前终止。

局限性

  • 研究因中期分析缺乏疗效而提前终止。
  • 摘要未报告样本量、入组人数及研究终止的具体时间点等信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: IL-13 is a potential therapeutic target for idiopathic pulmonary fibrosis (IPF); preclinical data suggest a role in tissue fibrosis, and expression is increased in subjects with rapidly progressing disease. OBJECTIVES: Investigate efficacy and safety of tralokinumab, a human anti-IL-13 monoclonal antibody, in subjects with mild to moderate IPF. METHODS: Subjects received tralokinumab (400 or 800 mg), or placebo, intravenously every 4 weeks for 68 weeks. The primary endpoint was change from baseline to Week 52 in percent predicted FVC in the intention-to-treat population. Exploratory analyses included assessment of clinical response in subgroups with baseline serum periostin concentration above/below median. MEASUREMENTS AND MAIN RESULTS: The study was stopped due to lack of efficacy after interim analysis. Neither tralokinumab 400 mg nor tralokinumab 800 mg met the primary endpoint; least-squares mean difference (95% confidence interval) percent predicted FVC from baseline to Week 52: -1.77 (-4.13 to 0.59) (P = 0.140) and -1.41 (-3.73 to 0.91) (P = 0.234), respectively. The primary endpoint was also not met in either treatment group in subgroups defined by periostin baseline concentration. The percentage of subjects with decline in percent predicted FVC greater than or equal to 10% at Week 52 was numerically greater for tralokinumab-treated subjects compared with placebo. The most common treatment-emergent adverse events for tralokinumab 400 mg, tralokinumab 800 mg, and placebo were cough (17.5, 30.5, 22.8%), IPF progression and exacerbation (21.1, 16.9, 22.8%), and upper respiratory tract infection (17.5, 20.3, 12.3%), respectively. CONCLUSIONS: Tralokinumab demonstrated an acceptable safety and tolerability profile but did not achieve key efficacy endpoints. Clinical trial registered with www.clinicaltrials.gov (NCT01629667).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Parker JM, Glaspole IN, Lancaster LH, et al. A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2018. PMID: 28787186. doi:10.1164/rccm.201704-0784OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。